Champions Oncology, Inc.
CSBR
NASDAQ·Healthcare·Biotechnology·Mkt cap $72.5M
$5.22
▼ -1.14%
P/E
-63.97
Mkt Cap
$72.5M
52-Wk Range
$4.83–$8.74
52-Week Range
$4.83 - $8.74
P/E
Fwd P/E
Beta
Div Yield
Avg Vol
Shares Out
Mkt Cap
Price action
Price chart
Down 23.2% over the trailing year
Total returns
Price performance
Total return across standard periods - splits & dividends adjusted by FMP. Periods longer than 1Y show annualized in the tooltip.
Why we rate it this way
The thesis at a glance
Bull and bear case · plain-English context across the five lenses we evaluate.
Bull Case
No bull reasons captured for this rating yet.
Bear Case
2 risks
- Low volatility (beta 0.4).
- High premium - requires strong execution
Growth
Turning profitable
Value
High premium - requires strong execution
Momentum
Weak
-7.6% over 3m
Quality
Strong
Mixed fundamentals
Dividend
None
No dividend
Smart-money signal
Who's buying CSBR right now
Insider Form 4s, 13F institutional filings, and Congressional disclosures - at a glance.
Earnings track record
Latest print - beat on both lines
AI-summarized recap of last quarter, plus the surprise on every print.
Next: Sep 10, 2026
JUL 27, 2026
Reported EPS of $0.01 vs -$0.05 consensus (+120.0% surprise). Revenue of $13.8M vs $12.9M expected (+7.4%). Beat on both top and bottom lines.
EPS surprise · last 4Q
1 of 1 beats
Estimate
Actual
Q3 26
+120.0%
Revenue trend · last 2Q
—
—
Q1 26
Q4 26
$14.0M
$0
Margins · last 2Q
Profit
—
Wall Street consensus
Analyst coverage
Live ratings and price targets aggregated across covering analysts.
vs Industry
How CSBR stacks vs Biotechnology
Stock metrics vs industry averages. Green = better than industry.
Industry comparison data unavailable for this stock.